Angiogenesis plays a pivotal role in malignant, ischemic, inflammatory, infectious and immune disorders. The increasing molecular understanding of angiogenic processes fostered the development of strategies to induce or inhibit angiogenesis for therapeutic purposes. Here, we focus on anti-angiogenic therapies, which represent a standard of care in the treatment of different cancer types and in neovascular age-related macular degeneration. Specifically, strategies related to the blockade of angiogenic proteins and receptors will be outlined covering both preclinical and clinical aspects. Finally, examples of gene therapy based anti-angiogenic approaches are presented.
CITATION STYLE
Büning, H., & Hacker, U. T. (2016, January 1). Inhibitors of Angiogenesis. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-3-319-32805-8_12
Mendeley helps you to discover research relevant for your work.